Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.

Current and future challenges in HCV: insights from an Italian experts panel / Andreoni, Massimo; Babudieri, Sergio; Bruno, Savino; Colombo, Massimo; Zignego, Anna L.; Di Marco, Vito; Di Perri, Giovanni; Perno, Carlo F.; Puoti, Massimo; Taliani, Gloria; Villa, Erica; Craxì, Antonio. - In: INFECTION. - ISSN 0300-8126. - 46:2(2018), pp. 147-163. [10.1007/s15010-017-1093-1]

Current and future challenges in HCV: insights from an Italian experts panel

Bruno, Savino;Di Marco, Vito;Taliani, Gloria;Villa, Erica;
2018

Abstract

Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.
2-nov-2017
46
2
147
163
Current and future challenges in HCV: insights from an Italian experts panel / Andreoni, Massimo; Babudieri, Sergio; Bruno, Savino; Colombo, Massimo; Zignego, Anna L.; Di Marco, Vito; Di Perri, Giovanni; Perno, Carlo F.; Puoti, Massimo; Taliani, Gloria; Villa, Erica; Craxì, Antonio. - In: INFECTION. - ISSN 0300-8126. - 46:2(2018), pp. 147-163. [10.1007/s15010-017-1093-1]
Andreoni, Massimo; Babudieri, Sergio; Bruno, Savino; Colombo, Massimo; Zignego, Anna L.; Di Marco, Vito; Di Perri, Giovanni; Perno, Carlo F.; Puoti, Massimo; Taliani, Gloria; Villa, Erica; Craxì, Antonio
File in questo prodotto:
File Dimensione Formato  
Andreoni2018_Article_CurrentAndFutureChallengesInHC.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 838.61 kB
Formato Adobe PDF
838.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1154127
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact